Showing 321-330 of 381 results for "".
- FDA Grants ReCell Expedited Access Pathway Designation to Treat Burnshttps://practicaldermatology.com/news/fda-grants-recell-expedited-access-pathway-designation-to-treat-burns/2458782/The FDA has ruled that the ReCell® Autologous Cell Harvesting Device from Avita Medical Ltd. is eligible for earlier regulatory approval for burns treatment. The ruling came under new FDA guidelines called the Expedited Access Pathway (EAP), which are aimed at helping patients get mor
- GSK: Positive Phase 3 Results for Benlysta® In Patients with Systemic Lupus Erythematosushttps://practicaldermatology.com/news/gsk-positive-results-phase-3-results-for-benlysta-in-patients-systemic-lupus-erythematosus/2458812/Results from the BLISS-SC Phase 3 pivotal study in patients with active, autoantibody-positive systemic lupus erythematosus (SLE) show that Benlysta®(belimumab) 200mg administered weekly via subcutaneous injection plus
- FDA Approves Juvederm® Ultra XC for Use in Lipshttps://practicaldermatology.com/news/fda-approves-juvederm-ultra-xc-for-use-in-lips/2458860/Allergan has received FDA approval to market Juvederm® Ultra XC for injection into the lips and perioral area for lip augmentation in adults over the age of 21. It is the only dermal filler that has proven results lasting up to one year for lip augmentation
- National Psoriasis Foundation Launches Patient-centered Research Platformhttps://practicaldermatology.com/news/national-psoriasis-foundation-launches-patient-centered-research-platform/2458902/Patients with psoriasis and psoriatic arthritis can contribute directly to the future of research into these chronic, systemic autoimmune diseases through the National Psoriasis Foundation’s patient-centered research network called Citizen Pscientist. This online, interactive community, all
- Radiesse from Merz Aesthetics Approved for Handshttps://practicaldermatology.com/news/radiesse-from-merz-aesthetics-approved-for-hands/2458934/Radiesse® from Merz Aesthetics received FDA approval for hand augmentation to correct volume loss in the dorsum of the hands. Radiesse® provides an immediate volumizing effect and can help to reduce the prom
- arGEN-X and LEO Pharma Enter into Alliance to Develop Antibody-based Treatments for Skin Conditionshttps://practicaldermatology.com/news/argen-x-and-leo-pharma-enter-into-alliance-to-develop-antibody-based-treatments-for-skin-conditions/2458940/arGEN-X, a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies to treat cancer and severe autoimmune diseases, and LEO Pharma entered into an alliance in which they will collaborate to develop antibody-based solutions for the treatment
- New App for Clinical Skin Cancer Diagnosis Launches on World Cancer Day 2015; Physician Input Soughthttps://practicaldermatology.com/news/new-app-for-clinical-skin-cancer-diagnosis-launches-on-world-cancer-day-2015-physician-input-sought/2459012/On World Cancer Day 2015, general practitioners, physicians, and dermatologists in the United States, United Kingdom and Australia were asked for their feedback during the advanced trial phase of a new, free app that has the potential to play a role in the clinical detection of skin cancer.
- Curcumin Nanoparticles Prevent Infections in Healing Woundshttps://practicaldermatology.com/news/20140922-curcumin_nanoparticles_prevent_infections_in_healing_wounds/2459114/Curcumin nanoparticles (curc-np) inhibit in vitro growth of methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa in dose-dependent fashion, and inhibits MRSA growth and enhances wound healing in an in vivo murine wound model, new research in the journal
- New Data Show High Efficacy for Can-Fite's CF101 in Rheumatoid Arthritis and Psoriasis Patientshttps://practicaldermatology.com/news/20140806-new_data_show_high_efficacy_for_can-fites_cf101_in_rheumatoid_arthritis_and_psoriasis_patients/2459151/New data from a retrospective analysis of its autoimmune disease advanced trials show high efficacy of Can-Fite BioPharma Ltd.'s orally bioavailable drug CF101.
- Promius Pharma Launches New Physician Portal to Track Patient Progress on Zenatanehttps://practicaldermatology.com/news/20140715-promius_pharma_launches_new_physician_portal_to_track_patient_progress_on_zenatane/2459169/A new web-based provider portal from Promius Pharma allows physicians to follow a patient's progress while taking Zenatane™(isotretinoin capsules USP) AB rated to Accutane. Designed to allow any authorized prescriber using the Promius Promise to obtain easy, instant access to secure patient data rel